Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.55% -0.01% 1.914B 89809.70
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0% 26.00% 96.13M Upgrade

Basic Info

Investment Strategy
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name First Trust
Prospectus Benchmark Index
NYSE Arca Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Daniel Lindquist 14.79 yrs
David McGarel 14.79 yrs
Jon Erickson 14.79 yrs
Roger Testin 14.79 yrs
Stan Ueland 14.41 yrs
Chris Peterson 5.04 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 21
96.13M
-4.178B Category Low
8.066B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of March 31, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of April 21, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
47.55%
10.90%
-19.59%
37.07%
-0.30%
19.74%
12.96%
-2.23%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
9.54%
33.83%
11.56%
-21.41%
21.08%
-9.53%
25.21%
26.01%
2.12%
25.60%
4.92%
-22.44%
15.99%
-13.12%
26.81%
24.92%
6.93%
36.34%
1.73%
-22.90%
22.28%
-0.19%
18.65%
25.66%
7.58%
--
--
-25.62%
13.57%
-20.62%
24.19%
36.52%
-6.07%
As of April 21, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (4-22-21) 0%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 25.59
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of April 21, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of April 21, 2021

Asset Allocation

As of April 21, 2021.
Type % Net % Long % Short
Cash 0.08% Upgrade Upgrade
Stock 99.92% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
FibroGen Inc 3.48% 21.55 2.33%
Exelixis Inc 3.44% 24.85 0.73%
United Therapeutics Corp 3.42% 211.45 -0.23%
Nektar Therapeutics 3.42% 20.18 2.28%
Alkermes PLC 3.40% 20.98 2.34%
Alexion Pharmaceuticals Inc 3.39% 168.33 -0.07%
Incyte Corp 3.37% 84.00 -0.85%
Ionis Pharmaceuticals Inc 3.35% 42.44 2.29%
IQVIA Holdings Inc 3.34% 226.98 3.64%
ACADIA Pharmaceuticals Inc 3.34% 21.55 0.37%

Basic Info

Investment Strategy
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name First Trust
Prospectus Benchmark Index
NYSE Arca Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Daniel Lindquist 14.79 yrs
David McGarel 14.79 yrs
Jon Erickson 14.79 yrs
Roger Testin 14.79 yrs
Stan Ueland 14.41 yrs
Chris Peterson 5.04 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (4-22-21) 0%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 25.59
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of April 21, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of April 21, 2021

Fund Details

Key Dates
Inception Date 6/19/2006
Last Annual Report Date 12/31/2020
Last Prospectus Date 5/1/2020
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No